Skip to main content
. 2023 Oct 18;83(1):26–40. doi: 10.1007/s12020-023-03526-0

Fig. 3.

Fig. 3

Patient’s plCT and CEA monitoring before and during treatment. LC Latero-Cervical, MCC Merkel Cell Carcinoma, CBZ cabozantinib, plCT Plasmatic Calcitonin, CEA Carcino-Embryonic Antigen